Aktis Oncology, Inc. (AKTS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Aktis Oncology, Inc. (AKTS) Healthcare & Pipeline Overview

Aktis Oncology, Inc., a clinical-stage biotechnology firm, specializes in targeted radiopharmaceutical therapies, utilizing its innovative miniprotein radioconjugate platform. Their lead candidates, AKY-1189 and AKY-2519, target Nectin-4 and B7-H3 expressing tumors, respectively, positioning them in the competitive oncology therapeutics market with a focus on precision medicine.

What Is the Investment Thesis for AKTS?

Aktis Oncology presents a compelling, albeit high-risk, investment opportunity within the radiopharmaceutical therapeutics sector. The company's miniprotein radioconjugate platform offers a novel approach to targeted cancer treatment, potentially improving efficacy and reducing side effects compared to traditional therapies. Key value drivers include the successful clinical development and commercialization of AKY-1189 and AKY-2519. Upcoming clinical trial results for AKY-1189 in urothelial cancer will be a critical catalyst. The company's ability to secure partnerships and funding to support ongoing research and development is also crucial. However, the company's negative profit margin of -970.2% and negative free cash flow of $-0.04B highlight the significant financial risks associated with clinical-stage biotechnology companies.

Based on FMP financials and quantitative analysis

AKTS Key Highlights

• Market capitalization of $1.29B reflects investor confidence in Aktis Oncology's technology and pipeline.
• Gross margin of 100.0% indicates the potential profitability of Aktis Oncology's radiopharmaceutical therapies upon commercialization, though it is currently based on limited revenue.
• P/E ratio of -12.17 reflects the company's current lack of profitability, typical for clinical-stage biotechnology companies.
• Aktis Oncology's focus on targeted radiopharmaceutical therapies aligns with the growing trend towards precision medicine in oncology.
• The company's lead product candidates, AKY-1189 and AKY-2519, target validated cancer targets, Nectin-4 and B7-H3, respectively, increasing the likelihood of clinical success.

Who Are AKTS's Competitors?

AKTS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AKTS's Key Strengths?

• Innovative miniprotein radioconjugate platform.
• Targeted approach to cancer treatment.
• Strong intellectual property portfolio.
• Experienced management team.

What Are AKTS's Weaknesses?

• Clinical-stage company with no approved products.
• High cash burn rate due to ongoing research and development.
• Reliance on successful clinical trial outcomes.
• Competition from established pharmaceutical companies.

What Could Drive AKTS Stock Higher?

• Clinical trial results for AKY-1189 in urothelial cancer.
• Initiation of clinical trials for AKY-2519 in prostate cancer.
• Expansion of the miniprotein radioconjugate platform to new cancer targets.
• Strategic partnerships with pharmaceutical companies for commercialization.

What Are the Key Risks for AKTS?

• Clinical trial failures for AKY-1189 and AKY-2519.
• Regulatory hurdles in obtaining approval for their therapies.
• Competition from other cancer therapies.
• Patent expiration and generic competition.
• High cash burn rate due to ongoing research and development.

What Are the Growth Opportunities for AKTS?

• Expansion of AKY-1189 into additional Nectin-4 expressing tumors: AKY-1189 is currently being developed for urothelial cancer, breast cancer, NSCLC, colorectal cancer, and cervical cancer. Expanding clinical trials to include other Nectin-4 expressing tumors could significantly increase the addressable market. The market for Nectin-4 targeted therapies is projected to grow as more cancers are found to express this target, offering a substantial growth opportunity for Aktis Oncology.
• Development of AKY-2519 for broader B7-H3 expressing solid tumors: AKY-2519 targets B7-H3 CD276 expressing tumors, including prostate and lung cancer. Expanding clinical trials to include other solid tumors with high B7-H3 expression could significantly broaden the potential patient population. The B7-H3 targeted therapy market is anticipated to expand as research validates its role in various cancers.
• Strategic partnerships with pharmaceutical companies: Collaborating with larger pharmaceutical companies could provide Aktis Oncology with access to resources, expertise, and distribution networks necessary for commercializing its therapies. These partnerships can accelerate clinical development and market penetration, enhancing the company's growth trajectory. The pharmaceutical industry is actively seeking innovative oncology therapies, making strategic alliances a viable growth avenue.
• Advancement of the miniprotein radioconjugate platform: Further development and refinement of the miniprotein radioconjugate platform could lead to the discovery of new radiopharmaceutical therapies targeting a wider range of cancer targets. This platform innovation can create a pipeline of novel therapies, driving long-term growth. Continuous innovation in radiopharmaceutical technology is crucial for maintaining a competitive edge.
• Geographic expansion into new markets: Initially focused on the US market, Aktis Oncology could expand its operations to Europe and Asia, where there is a growing demand for advanced cancer therapies. Entering these markets would require regulatory approvals and strategic partnerships, but it could significantly increase the company's revenue potential. The global oncology market is expanding, presenting opportunities for companies to establish a global presence.

What Opportunities Does AKTS Have?

• Expansion into new cancer indications.
• Strategic partnerships with pharmaceutical companies.
• Advancement of the miniprotein radioconjugate platform.
• Geographic expansion into new markets.

What Threats Does AKTS Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from other cancer therapies.
• Patent expiration.

What Are AKTS's Competitive Advantages?

• Proprietary miniprotein radioconjugate platform for targeted drug delivery.
• Strong intellectual property portfolio protecting their radiopharmaceutical therapies.
• Clinical data demonstrating the efficacy and safety of their therapies.
• Expertise in radiopharmaceutical development and manufacturing.
• Potential for strategic partnerships with larger pharmaceutical companies.

What Does AKTS Do?

Aktis Oncology, Inc., founded in 2020 and based in Boston, Massachusetts, is a clinical-stage oncology company dedicated to developing targeted radiopharmaceutical therapies for cancer treatment. Originally named HotKnot Therapeutics, Inc., the company rebranded to Aktis Oncology, Inc. in April 2020 to reflect its focus on actinium-based therapies. Aktis Oncology operates a miniprotein radioconjugate platform designed to discover and develop radiopharmaceutical therapies. This platform facilitates the delivery of tumor-killing radioisotopes directly to cancer cells, minimizing damage to healthy tissue. Their lead product candidates include AKY-1189, a miniprotein radioconjugate targeting Nectin-4 expressing tumors, and AKY-2519, which targets B7-H3 CD276 expressing tumors. AKY-1189 is being developed for the treatment of locally advanced or metastatic urothelial cancer, as well as breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. AKY-2519 is designed for the treatment of prostate cancer, lung cancer, and other solid tumors. Aktis Oncology's approach aims to improve the efficacy and safety of cancer treatment by selectively targeting cancer cells with radioactive isotopes.

What Products and Services Does AKTS Offer?

• Develop targeted radiopharmaceutical therapies for cancer treatment.
• Utilize a miniprotein radioconjugate platform to deliver radioisotopes to tumors.
• Offer AKY-1189 for the treatment of Nectin-4 expressing tumors.
• Offer AKY-2519 for the treatment of B7-H3 CD276 expressing tumors.
• Focus on precision medicine by selectively targeting cancer cells.
• Conduct clinical trials to evaluate the safety and efficacy of their therapies.

How Does AKTS Make Money?

• Develop and patent novel radiopharmaceutical therapies.
• Conduct preclinical and clinical trials to demonstrate efficacy and safety.
• Seek regulatory approval from agencies like the FDA.
• Potentially partner with larger pharmaceutical companies for commercialization.
• Generate revenue through sales of approved therapies or licensing agreements.

What Industry Does AKTS Operate In?

Aktis Oncology operates within the rapidly evolving radiopharmaceutical therapeutics market. This market is driven by the increasing demand for targeted cancer therapies with improved efficacy and reduced toxicity. The competitive landscape includes established pharmaceutical companies and specialized biotechnology firms developing radiopharmaceuticals. Aktis Oncology's miniprotein radioconjugate platform differentiates it from competitors by offering a potentially more precise and efficient method of delivering radioisotopes to cancer cells.

Who Are AKTS's Key Customers?

• Patients with locally advanced or metastatic urothelial cancer.
• Patients with breast cancer, NSCLC, colorectal cancer, and cervical cancer.
• Patients with prostate cancer, lung cancer, and other solid tumors.
• Oncologists and other healthcare professionals who treat cancer patients.
• Hospitals and cancer centers that administer radiopharmaceutical therapies.

Aktis Oncology, Inc. (AKTS) Valuation Context

Valued at $1.29B, AKTS is classified as a small-cap stock. Relative to its peer group, AKTS's quantitative score of 30/100 is below the peer average of 86/100.

AKTS Revenue & Earnings Trend

In Q1 2026, AKTS generated $3.2M in top-line revenue, marking a sequential increase of 72.6%. The company recorded a net loss of $18.3M, with diluted EPS of $-0.33. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company.

Company Profile

Aktis Oncology, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Matthew Roden. AKTS has traded publicly since 2026.

Key Financial Metrics

Return on assets is -7.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 19.49 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.2%, the inverse of the P/E and a quick read on earnings relative to price.

FY2026 estForward Outlook

Wall Street analysts project Aktis Oncology, Inc. revenue of about $16.8M for fiscal 2026, with EPS near $-1.63. The estimate reflects 5 contributing analysts.

AKTS Financials

AKTS Latest News

AKTS Analyst Consensus

AKTS MoonshotScore

What Investors Ask About Aktis Oncology, Inc. (AKTS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources